Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $81.50 Average PT from Brokerages

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $81.50.

Several research firms have recently commented on RARE. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 9th. Morgan Stanley decreased their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, July 14th. William Blair assumed coverage on shares of Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They set an “outperform” rating and a $65.00 price target on the stock. Canaccord Genuity Group decreased their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, Wells Fargo & Company decreased their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating for the company in a research note on Thursday, July 10th.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,450 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $31.17, for a total value of $76,366.50. Following the completion of the sale, the executive vice president owned 73,271 shares in the company, valued at approximately $2,283,857.07. This trade represents a 3.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its position in shares of Ultragenyx Pharmaceutical by 28.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company’s stock valued at $116,559,000 after acquiring an additional 706,519 shares during the period. Adage Capital Partners GP L.L.C. grew its position in shares of Ultragenyx Pharmaceutical by 81.6% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company’s stock valued at $77,815,000 after acquiring an additional 965,919 shares during the period. Federated Hermes Inc. grew its position in shares of Ultragenyx Pharmaceutical by 0.3% during the 1st quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company’s stock valued at $74,419,000 after acquiring an additional 5,400 shares during the period. Geode Capital Management LLC grew its position in shares of Ultragenyx Pharmaceutical by 4.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,712,931 shares of the biopharmaceutical company’s stock valued at $62,291,000 after acquiring an additional 66,394 shares during the period. Finally, Deutsche Bank AG grew its position in shares of Ultragenyx Pharmaceutical by 0.5% during the 1st quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company’s stock valued at $61,611,000 after acquiring an additional 8,385 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE opened at $29.11 on Tuesday. The firm has a 50-day moving average of $29.00 and a 200-day moving average of $34.10. The company has a market cap of $2.81 billion, a PE ratio of -5.26 and a beta of 0.21. Ultragenyx Pharmaceutical has a one year low of $25.81 and a one year high of $59.90.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. The company had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The firm’s revenue for the quarter was up 13.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.